{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:44:19Z","timestamp":1793749459692,"version":"4.6.1"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Intensity-modulated radiation therapy (IMRT) reirradiation of nonmetastatic recurrent or second primary head and neck squamous cell carcinoma (HNSCC) results in poor progression-free survival (PFS) and overall survival (OS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate the tolerability, PFS, OS, and patient-reported outcomes with nivolumab (approved standard of care for patients with HNSCC) during and after IMRT reirradiation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>In this multicenter nonrandomized phase 2 single-arm trial, the treatment outcomes of patients with recurrent or second primary HNSCC who satisfied recursive partitioning analysis class 1 and 2 definitions were evaluated. Between July 11, 2018, and August 12, 2021, 62 patients were consented and screened. Data were evaluated between June and December 2023.<\/jats:p><\/jats:sec><jats:sec><jats:title>Intervention<\/jats:title><jats:p>Sixty- to 66-Gy IMRT in 30 to 33 daily fractions over 6 to 6.5 weeks with nivolumab, 240 mg, intravenously 2 weeks prior and every 2 weeks for 5 cycles during IMRT, then nivolumab, 480 mg, intravenously every 4 weeks for a total nivolumab duration of 52 weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary end point was PFS. Secondary end points included OS, incidence, and types of toxic effects, including long-term treatment-related toxic effects, patient-reported outcomes, and correlatives of tissue and blood biomarkers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 62 patients were screened, and 51 were evaluable (median [range] age was 62 [56-67] years; 42 [82%] were male; 6 [12%] had p16+ disease; 38 [75%] had salvage surgery; and 36 [71%.] had neck dissection). With a median follow-up of 24.5 months (95% CI, 19.0-25.0), the estimated 1-year PFS was 61.7% (95% CI, 49.2%-77.4%), rejecting the null hypothesis of 1-year PFS rate of less than 43.8% with 1-arm log-rank test <jats:italic>P<\/jats:italic>\u2009=\u2009.002 within a 1-year timeframe. The most common treatment-related grade 3 or higher adverse event (6 [12%]) was lymphopenia with 2 patients (4%) and 1 patient each (2%) exhibiting colitis, diarrhea, myositis, nausea, mucositis, and myasthenia gravis. Functional Assessment of Cancer Therapy\u2013General and Functional Assessment of Cancer Therapy\u2013Head and Neck Questionnaire quality of life scores remained stable and consistent across all time points. A hypothesis-generating trend favoring worsening PFS and OS in patients with an increase in blood PD1+, KI67+, and CD4+ T cells was observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>This multicenter nonrandomized phase 2 trial of IMRT reirradiation therapy and nivolumab suggested a promising improvement in PFS over historical controls. The treatment was well tolerated and deserves further evaluation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03521570\">NCT03521570<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2024.1143","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T15:33:10Z","timestamp":1716478390000},"page":"896","source":"Crossref","is-referenced-by-count":25,"title":["Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma"],"prefix":"10.1001","volume":"10","author":[{"given":"Nabil F.","family":"Saba","sequence":"first","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia"},{"name":"Winship Cancer Institute, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart J.","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical College of Wisconsin, Pleasant Prairie"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahseen","family":"Nasti","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, Georgia"},{"name":"The Emory Vaccine Center, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley Alesia","family":"McCook-Veal","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, Georgia"},{"name":"Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"McDonald","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, Georgia"},{"name":"Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Stokes","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, Georgia"},{"name":"Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allyson M.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asari","family":"Ekpenyong","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manali","family":"Rupji","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, Georgia"},{"name":"Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marin","family":"Abousaud","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development Inc, Northbrook, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumon","family":"Rudra","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, Georgia"},{"name":"Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Bates","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, Georgia"},{"name":"Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill S.","family":"Remick","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, Georgia"},{"name":"Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil P.","family":"Joshi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil M.","family":"Woody","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musaddiq","family":"Awan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical College of Wisconsin, Pleasant Prairie"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L.","family":"Geiger","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Shreenivas","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical College of Wisconsin, Pleasant Prairie"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Samsa","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew Christopher","family":"Ward","sequence":"additional","affiliation":[{"name":"Radiation Therapy Center, Atrium Health Levine Cancer Institute, Charlotte, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole C.","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, Georgia"},{"name":"Department of Otolaryngology, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihir R.","family":"Patel","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, Georgia"},{"name":"Department of Otolaryngology, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin A.","family":"Higgins","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, Georgia"},{"name":"Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Teng","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia"},{"name":"Winship Cancer Institute, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor E.","family":"Steuer","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia"},{"name":"Winship Cancer Institute, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong M.","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia"},{"name":"Winship Cancer Institute, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, Georgia"},{"name":"Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafi","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, Georgia"},{"name":"The Emory Vaccine Center, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomo A.","family":"Koyfman","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10318","key":"coi240013r1","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/S0140-6736(21)01550-6","article-title":"Head and neck cancer.","volume":"398","author":"Mody","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"coi240013r2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer.","volume":"363","author":"Ang","year":"2010","journal-title":"N Engl J Med"},{"issue":"20","key":"coi240013r3","doi-asserted-by":"publisher","first-page":"6542","DOI":"10.1158\/1078-0432.CCR-10-1604","article-title":"High XRCC1 protein expression is associated with poorer survival in patients with head and neck squamous cell carcinoma.","volume":"17","author":"Ang","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"1","key":"coi240013r4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.14338\/IJPT-20-00064.1","article-title":"A systematic review on re-irradiation with charged particle beam therapy in the management of locally recurrent skull base and head and neck tumors.","volume":"8","author":"Gamez","year":"2021","journal-title":"Int J Part Ther"},{"issue":"13","key":"coi240013r5","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.3390\/cancers13133173","article-title":"Re-irradiation for head and neck cancer: cumulative dose to organs at risk and late side effects.","volume":"13","author":"Embring","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"coi240013r6","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.ijrobp.2006.12.055","article-title":"Salvage re-irradiation for recurrent head and neck cancer.","volume":"68","author":"Lee","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"coi240013r7","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.radonc.2016.08.020","article-title":"Benefit of particle therapy in re-irradiation of head and neck patients: results of a multicentric in silico ROCOCO trial.","volume":"121","author":"Eekers","year":"2016","journal-title":"Radiother Oncol"},{"issue":"3","key":"coi240013r8","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.ijrobp.2017.06.012","article-title":"Refining patient selection for reirradiation of head and neck squamous carcinoma in the IMRT era: a multi-institution cohort study by the MIRI collaborative.","volume":"100","author":"Ward","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"34","key":"coi240013r9","doi-asserted-by":"publisher","first-page":"5518","DOI":"10.1200\/JCO.2007.15.0102","article-title":"Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma.","volume":"26","author":"Janot","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi240013r10","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1200\/JCO.21.01752","article-title":"Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: an ECOG-ACRIN Cancer Research Group Trial (E3311).","volume":"40","author":"Ferris","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10212","key":"coi240013r11","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"issue":"127","key":"coi240013r12","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.","volume":"4","author":"Taube","year":"2012","journal-title":"Sci Transl Med"},{"issue":"6","key":"coi240013r13","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1158\/0008-5472.CAN-12-2384","article-title":"Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma.","volume":"73","author":"Lyford-Pike","year":"2013","journal-title":"Cancer Res"},{"issue":"8","key":"coi240013r14","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/hed.v37.8","article-title":"Expression profile and in vitro blockade of programmed death-1 in human papillomavirus\u2013negative head and neck squamous cell carcinoma.","volume":"37","author":"Malm","year":"2015","journal-title":"Head Neck"},{"issue":"19","key":"coi240013r15","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck.","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"coi240013r16","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1093\/oncolo\/oyab036","article-title":"Long-term outcomes with nivolumab as first-line treatment in recurrent or metastatic head and neck cancer: subgroup analysis of CheckMate 141.","volume":"27","author":"Gillison","year":"2022","journal-title":"Oncologist"},{"key":"coi240013r17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.oraloncology.2019.01.022","article-title":"A competing risk nomogram to predict severe late toxicity after modern re-irradiation for squamous carcinoma of the head and neck.","volume":"90","author":"Ward","year":"2019","journal-title":"Oral Oncol"},{"issue":"3","key":"coi240013r18","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1177\/17407745221093922","article-title":"Methodological standards for using the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in cancer clinical trials.","volume":"19","author":"Basch","year":"2022","journal-title":"Clin Trials"},{"issue":"6332","key":"coi240013r19","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1126\/science.aaf0683","article-title":"Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent.","volume":"355","author":"Kamphorst","year":"2017","journal-title":"Science"},{"issue":"7652","key":"coi240013r20","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"issue":"19","key":"coi240013r21","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.1073\/pnas.1705327114","article-title":"Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients.","volume":"114","author":"Kamphorst","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"coi240013r22","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41379-020-00710-9","article-title":"Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer.","volume":"34","author":"Emancipator","year":"2021","journal-title":"Mod Pathol"},{"key":"coi240013r23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.oraloncology.2018.05.012","article-title":"Prospective evaluation of patient reported swallow function with the Functional Assessment of Cancer Therapy (FACT), MD Anderson Dysphagia Inventory (MDADI) and the Sydney Swallow Questionnaire (SSQ) in head and neck cancer patients.","volume":"84","author":"Peng","year":"2018","journal-title":"Oral Oncol"},{"issue":"3","key":"coi240013r24","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The functional assessment of cancer therapy scale: development and validation of the general measure.","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol"},{"key":"coi240013r25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2155-6180","article-title":"A new one-sample log-rank test.","volume":"5","author":"Wu","year":"2014","journal-title":"J Biom Biostat"},{"issue":"1","key":"coi240013r26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/pst.1654","article-title":"Sample size calculation for the one-sample log-rank test.","volume":"14","author":"Wu","year":"2015","journal-title":"Pharm Stat"},{"issue":"2","key":"coi240013r27","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3109\/10428194.2012.711830","article-title":"The Functional Assessment of Cancer Therapy\u2013General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma.","volume":"54","author":"Yost","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"coi240013r28","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1007\/s00262-018-2228-7","article-title":"T cell receptor sequencing of activated CD8 T cells in the blood identifies tumor-infiltrating clones that expand after PD-1 therapy and radiation in a melanoma patient.","volume":"67","author":"Wieland","year":"2018","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"coi240013r29","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.4065\/82.10.1244","article-title":"Precision of health-related quality-of-life data compared with other clinical measures.","volume":"82","author":"Hahn","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"7875","key":"coi240013r30","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41586-020-2931-3","article-title":"Defining HPV-specific B cell responses in patients with head and neck cancer.","volume":"597","author":"Wieland","year":"2021","journal-title":"Nature"},{"issue":"7875","key":"coi240013r31","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41586-021-03862-z","article-title":"Functional HPV-specific PD-1+ stem-like CD8 T cells in head and neck cancer.","volume":"597","author":"Eberhardt","year":"2021","journal-title":"Nature"},{"issue":"10","key":"coi240013r32","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1245\/ASO.2004.02.018","article-title":"Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma.","volume":"11","author":"Hsueh","year":"2004","journal-title":"Ann Surg Oncol"},{"issue":"24","key":"coi240013r33","doi-asserted-by":"publisher","first-page":"5688","DOI":"10.1182\/blood-2011-10-386482","article-title":"Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer.","volume":"119","author":"Yao","year":"2012","journal-title":"Blood"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2819049\/jamaoncology_saba_2024_oi_240013_1720732631.36087.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T15:04:35Z","timestamp":1721315075000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2819049"}},"subtitle":["A Nonrandomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2024.1143","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,1]]}}}